RxDoctor Payments DataLook up a doctor →

Andrew Wang, MD

Dermatology · West Roxbury, MANPI 1417184144

Payments from drug & device makers

$96,919in general payments, 2019–2025

Across 619 payments — averaging $156.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$51K
  • E.r. Squibb & Sons, L.L.C.$16K
  • Novartis$9K
  • Pfizer$5K
  • UCB, Inc.$4K
  • AbbVie$3K
  • plus $8K from 21 others

What the payments were for

  • Consulting fees$27,99329%
  • Speaking & faculty fees$48,86850%
  • Grants$10%
  • Travel & lodging$2,8383%
  • Food & beverage$16,74917%
  • Education$4710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$96,919 in reported general payments places this provider in the 90th percentile of 552 dermatology providers in Massachusetts.

See all dermatology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$306,744
Medicare patients
713
Services billed
4,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa12$250,188
Dupixent PenDupilumab65$248,976
Taltz AutoinjectorIxekizumab19$130,040
OtezlaApremilast19$86,381
RinvoqUpadacitinib11$69,400
Clobetasol Propionate128$5,739
Ketoconazole248$4,726
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc71$3,011
Metronidazole58$2,932
Betamethasone Dipropionate80$2,863
Triamcinolone Acetonide280$2,348
Tacrolimus17$1,801
Fluorouracil28$1,633
Clindamycin Phosphate54$1,234
Azelaic Acid12$1,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$50,597$86,38119 claims
AbbVieRinvoq$2,980$69,40011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 552 dermatology providers in Massachusetts.

Other dermatology in West Roxbury

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →